Dr. Lal PathLabs (LALPATHLAB) Q2 24/25 earnings summary

Executive summary

• Achieved highest-ever quarterly revenue of INR 660 crore in Q2 FY25, up 9.8% year-over-year, and H1 FY25 revenue of INR 1,262 crore, up 10.5% year-over-year.

• PAT grew 18.1% year-over-year in Q2 FY25 to INR 131 crore, with robust profitability driven by operational leverage and cost optimization.

• Maintained strong market position in a fragmented diagnostics industry through brand strength, service quality, and network expansion, especially in Tier 3 and 4 regions.

• Focused on digital integration, home diagnostics, and expanding bundled test packages to drive patient volume and efficiency without price hikes.

• Leadership transition announced: Dr. Om Prakash Manchanda to move from Managing Director to advisory role after March 2025.

Financial highlights

• Q2 FY25 revenue at INR 660 crore, up 9.8% year-over-year; H1 FY25 revenue at INR 1,262 crore, up 10.5%.

• Q2 FY25 EBITDA at INR 202 crore (13.9% growth), margin at 30.7%; H1 FY25 EBITDA at INR 372 crore (15% growth), margin at 29.5%.

• Q2 FY25 PAT at INR 131 crore, up 18.1% year-over-year, margin at 19.8%; H1 FY25 PAT at INR 239 crore, up 22.8%, margin at 18.9%.

• Earnings per share for Q2 FY25 at INR 15.5, H1 FY25 at INR 28.3.

• Net cash as of September 30, 2024, at INR 1,095 crore; DSO at 25 days; negative working capital of 22 days.

• Second interim dividend of INR 6 per share approved for FY25.

Outlook and guidance

• Revenue growth guidance maintained at equal to or better than last year’s 10.4%; H1 FY25 delivered 10.5%.

• No price increases planned for FY25; focus remains on volume and network expansion.

• Margin guidance: expect full-year margins to be slightly better than last year, but Q2 margins not representative of full year due to seasonality and investments.

• CapEx guidance for FY25 remains at INR 50-60 crore, with most spending in H2.

• On track to open 15-20 new labs and add ~800 collection centers across both brands in FY25.